awmsg logo



dolutegravir/abacavir/lamivudine (Triumeq®)


Reference No. 2365

Publication date:
20/05/2015


Appraisal information

dolutegravir/abacavir/lamivudine (Triumeq®) 50 mg/600 mg/300 mg film-coated tablet


Company: ViiV Healthcare UK Ltd
BNF category: Infections
NMG meeting date: 25/02/2015
AWMSG meeting date: 25/03/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0415
Ministerial ratification: 15/05/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Dolutegravir/abacavir/lamivudine (Triumeq®) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download